Bayer Reports Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin’s Lymphoma

April 12, 2021 Auto Bot Bayer, Clinical Trials, Report, results, Rituximab 0

Shots:

  • The P-III CHRONOS-3 study involves assessing Aliqopa (IV) + rituximab vs PBO + rituximab in 458 patients with relapsed iNHL in extending PFS who have received at least one or more lines of prior rituximab-containing treatment
  • Results: @median follow-up of 19.2mos., mPFS (21.5 vs 13.8 mos.), ORR (80.8% vs 47.7%), CR (33.9% and 14.6%), no new safety signals were identified, overall improvement in the prognosis of iNHL patients
  • Aliqopa is a PI3K inhibitor with inhibitory activity against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. The data is presented at AACR 2021 and simultaneously published in The Lancet Oncology

Click here to­ read full press release/ article | Ref: Businesswire | Image: Business Standard

The post Bayer Reports Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin’s Lymphoma first appeared on PharmaShots.